NF- kappa B p65 Antibody detects endogenous levels of NF- kappa B p65. NFKB1 (MIM 164011) or NFKB2 (MIM 164012) is bound to REL (MIM 164910), RELA, or RELB (MIM 604758) to form the NFKB complex. The p50 (NFKB1)/p65 (RELA) heterodimer is the most abundant form of NFKB. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA, MIM 164008 or NFKBIB, MIM 604495), which inactivate NFKB by trapping it in the cytoplasm. Phosphorylation of serine residues on the I-kappa-B proteins by kinases (IKBKA, MIM 600664, or IKBKB, MIM 603258) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NFKB complex. Activated NFKB complex translocates into the nucleus and binds DNA at kappa-B-binding motifs such as 5-prime GGGRNNYYCC 3-prime or 5-prime HGGARNYYCC 3-prime (where H is A, C, or T; R is an A or G purine; and Y is a C or T pyrimidine).

Target	NFkB p65
Reactivity	Human, Mouse
Host	Rabbit
Clonality	Polyclonal
Tested Applications	WB, IHC, IF/ICC
Recommended dilutions	WB: 1/500 - 1/2000, IHC: 1/50 - 1/200, IF/ICC: 1/100 - 1/500. Optimal dilutions/concentrations should be determined by the end user.
Immunogen	A synthesized peptide derived from human NF- kappa B p65.
Purification	Immunogen affinity purified.
Conjugation	Unconjugated
Storage	Aliquot and store at -20 °C. Avoid repeated freeze/thaw cycles.
Molecular Weight	65 kDa
Swiss Prot	Q04206
Buffer	Rabbit IgG in PBS, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Availability	Shipped within 5-10 working days.
Note	This product is for research use only.